The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients
- Registration Number
- NCT00767897
- Lead Sponsor
- Indiana University
- Brief Summary
The proposed study is a pilot study and a first step towards developing an optimized HPV vaccination strategy for girls who have CKD, or are on dialysis or have a kidney transplant.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 72
Inclusion Criteria
- 9-18-year-old girls who have CKD stages 3 or 4 (Glomerular filtration rates 15-59 mL/min/1.73m2).
- 9-18-year-old girls who are on dialysis.
- 9-18-year-old girls who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen.
- Healthy 9-18-year-old girls
Exclusion Criteria
- Pregnancy, fever, allergy to any vaccine component, any immune disorder and any blood product received in the previous 6 months.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description CKD stage 3 or 4 Human Papillomavirus Vaccine Girls and Boys age 9-18 with CKD stage 3 or 4 On dialysis Human Papillomavirus Vaccine Girls and Boys age 9-18 who are on dialysis Transplanted Human Papillomavirus Vaccine Girls and Boys age 9-18 who have had a functioning kidney transplant for longer than 6 months and are on the same immunosuppression regimen. Healthy Human Papillomavirus Vaccine Girls and Boys age 9-18
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Indiana University/Riley Children's Hospital
🇺🇸Indianapolis, Indiana, United States